%PDF-1.7 % 28 0 obj << /Type /Page /Parent 1 0 R /LastModified (D:20240426123904+02'00') /Resources 2 0 R /MediaBox [0.000000 0.000000 595.276000 841.890000] /CropBox [0.000000 0.000000 595.276000 841.890000] /BleedBox [0.000000 0.000000 595.276000 841.890000] /TrimBox [0.000000 0.000000 595.276000 841.890000] /ArtBox [0.000000 0.000000 595.276000 841.890000] /Contents 29 0 R /Rotate 0 /Group << /Type /Group /S /Transparency /CS /DeviceRGB >> /Annots [ 5 0 R ] /PZ 1 >> endobj 29 0 obj <> stream xZ]s6}ϯyHfeoIf&f71nAVKKݟљ k;ΗS؄ >8{dۖߵql>}C9Lؖ]n,ܳ]YeCln iu8£h6 $\]!??9Mz)ceKF{ծmxk=g3n8w, vﻳ( XU= R8}ײNv8haHŗ*b8δ`3+Vy"G4y-"tkB8`X"w*g3"N\ $t$Ui,Ղc%%n_aNa0<"vWrhf ,&ؽ"@nw ]n۱_Y/<"6O,9qbO]-LEܲM~#=Pqosd?|luغtD1V)R2< cDwyc)i,(X,/6c#0G2C r! nА4OR?+^KH|S yjn0Ib^41fQKk)rY3&5H)πn[SXSdڅ) iz8 c9YqSx'Orkuib endstream endobj 30 0 obj << /Type /Page /Parent 1 0 R /LastModified (D:20240426123904+02'00') /Resources 2 0 R /MediaBox [0.000000 0.000000 595.276000 841.890000] /CropBox [0.000000 0.000000 595.276000 841.890000] /BleedBox [0.000000 0.000000 595.276000 841.890000] /TrimBox [0.000000 0.000000 595.276000 841.890000] /ArtBox [0.000000 0.000000 595.276000 841.890000] /Contents 31 0 R /Rotate 0 /Group << /Type /Group /S /Transparency /CS /DeviceRGB >> /Annots [ 6 0 R 7 0 R 8 0 R 9 0 R 10 0 R ] /PZ 1 >> endobj 31 0 obj <> stream x\r8}WC*CR1kgv&$RI C;u';SSd9 0a0s޾LJ ?{G,6~ Z-([ ~ F}@oڧ|LKiE' ^}\8>6^~$~L9vHGa0$4 8,(Ej`˚KB“0{N/}Y]Gwz4siqM=7z&&q4 Bp„HsgLԿ5N_ ") )U{x,-L% d3m e28 h&C8h$bF\p8A"#?{I|`8Ve/й14<˅>$رe KB0< JbqSFzys>\j_Ua1b)B ];e>Hxl06P`Y9FZ:s‘Mlƛ_*CG~hH : dG<䭉5wMVP_K%1BP6kZ7\xt@Z(Ӄ\pOka/)Gлu;? A3*N8j`%q0l]72DP.C;&㒻n04բVle<|G(=8 N0 ās`BKf|MϹ3dݣA<\a (F]&V Oq)x cB.r[4a{}o692_&4(5_6ժ^P\,/t`:cI3tثW3ND)Ê :7 ֽN4>6WdԢC680e_F{Csu= +lY} Um ^O.UN.ĺ%¯Cmoud!Ptø-躏Mپ{R_bàMk0i+n&Y,ւJ5hc kq\RuUFZg]kl&RfiyM RԨ5/ҊpkYkq}%D>JI ٤gV_JB t0zq&.%׀U UMFz{t\ؐr]3..sc / .F%?kiZ.޳h&wmy:W ?h&{8ݺw *ab1^06kV{BrI꒗s|UOVD#udUS+~Qh+s5$$3N}aLkǘJӶɗn&;5gnUv% D{{+ޯg=l0u܋3yWdÉG: ƣd0m{ݯ>IѢr7IҭqNԾw4Ip^`̝/t_vn}wo:1^hWD9ݛ%CCjaV࿟8[%ăp/D-_yA7?F{S-֑)5\JPD`lb|#"({ZV6]qyM`YK&8_yR|rDF/$TOmXn]Ί jtI@I0PzJo?{[FW_ "_za!Q+'=۪pڝ ~/zzfke/;qr*w]dZ w:P1 ~.k7+{r^*g +xsVbٗwOMRB0`ݧIoA\QhL1}إQZ5ï( c >0_0n(Ӫ 9#<mXjM`hJ{uބQ5@B9yzAh1pC\0}d̹OICeoK΃?qU/y endstream endobj 32 0 obj << /Type /Page /Parent 1 0 R /LastModified (D:20240426123904+02'00') /Resources 2 0 R /MediaBox [0.000000 0.000000 595.276000 841.890000] /CropBox [0.000000 0.000000 595.276000 841.890000] /BleedBox [0.000000 0.000000 595.276000 841.890000] /TrimBox [0.000000 0.000000 595.276000 841.890000] /ArtBox [0.000000 0.000000 595.276000 841.890000] /Contents 33 0 R /Rotate 0 /Group << /Type /Group /S /Transparency /CS /DeviceRGB >> /Annots [ 11 0 R 12 0 R ] /PZ 1 >> endobj 33 0 obj <> stream x\[s6}c;SHv\i̶(D$e{>@q4ɦzBw;(0ξϯ_kx{><-/LlɜNd^w$|0Qcu)~OW'쇃ػ2j\1|%a7FB O"LXc0l2c?ƞ6tYV4_ʢe`bUWm]1c"šZXӮ.첬f-j(O%CźVWm7<&x~WjJ҈zrmVɴX.vֱe^]NsXYuESby5-B7fQ4[޶u[Ӣdh)?nW0˦_Y}V+`*k,|9+/s"fΫlbY-O~u~YҌmhiȱbux,+X; oBT.^F  ixAeI-sͤ"Mh`+a,-)gef,6yWׅ 6żɧH#]B5ySVDVs㪾,e~,6܄w>܌EQ5rIbl)Zi8/?r.y]9{bh$Lο:$sk8T\mW^aQk',"w!ߠzרnj۷xqʐ ȴT]s|^tdJo&} #E_6ك"8C.]@Eˮ5җj_y+| Yդe|z_M0ˢ!9"9*'yYN%\zy[{\H2b̊'*& 4]-KDp<.}zЙw3W^^A61:}6y^|3|lVB*SmtrsQN^"wy3]0ɅA)({d}K^+þE$w _V'iO"_F "w*GO|iK림Ztmr)*jKxQ?%ƄuO%!z6 df m="$+LglVcجKf{|S_d' -\k'v(=d[# F߱)9f= GEJu[ҶߺlaWfQ=(nfêF,Z7A]yHw5k- or^L:Rr'+7BA(T3ںNe-6죄9>:\ [H7_Iݷ CIݝ9_ l@FGOT3Dh$F5wşzwZ uPAC^V򲤣i]܍{RN̨>}^bys_bPx}2{89!:-e'Y4ҌcEَ67=?BZۥ|, Xyl`<W%&a5̪3dL*cJ=dX`6]M9xRvڔG =qYTżQ,f=/UNv$=K̾Z|(޶6zK/ss޿s(G!UbսlONARMΎ'Ͽa'gG>~ճ?t<;>4^/#׻ۏ:p6ѽ"`;LSe-#PiI0V:Љ3)D$h=h:FKi{P:( IV/V 9aKG8V``2V &``֠@~T6}LiMvlj ~ ;@$Vf%ux1BK:d(a0ŷAU GgNd d)`EAr΄%<3m >3m,1Ei`a"s0 sFɕ-ykHC"qއ͉>7nKxFEš[`LcW?.JzgfkHn]O_)ٓ{]ͪЪ2}$uwt-@߫)uC;&{K&';⢿iڟjn/-66ij#jGE )n[IEnQ4*nh;nڢӎXل-=-U^a,{ Jӵ\~gDբ"_F5s^=Mپ|4>( DU1+J0S"kz#Pj<ѫ;rr"6<νjȽ!O8Q'0b$ Fe*t]A`jQ#&8CHZ4*,U@jZFҚ`ޘHZ{Т,7Q F *G2;:AQ( `F҃QJ HZ{8u$=nJ؃ Zu-\$TnkUz$=,1Ik?&RԐj$=,d$=ZFză)dIk8xHZ{6RD~m3v=< *]Ikr}aɼu#i-1PqVAZg*`sHZ{Q`&w&im"]NA 8hXJiک]2>iHZxCUļUw:H둴&fea y4N[!n$!AEo`p6x#iM0[Kch^ڌ'Lۑ&.cq0#G6HZ,bұ< zdƔIkTܙHZ{QHZ{%LP*IED$=uvn53#ia"i UT -[>֞[$XjkmXǰa}܌PAofCI΍ fHZ{*銦P/GPCfڦALwhQr5D }Q"Tqiһ0HZ{w(EC w4[`|rZcWMSP);pyWU^Mo ~6(es[ ԋYW?*_Mk\ڠ]J&%Sb>tέ}9{gw{zSuA3O}2><\"ڂбE7!ީ[/̷l*>[C5;/]ol>L*=LklY endstream endobj 34 0 obj << /Type /Page /Parent 1 0 R /LastModified (D:20240426123904+02'00') /Resources 2 0 R /MediaBox [0.000000 0.000000 595.276000 841.890000] /CropBox [0.000000 0.000000 595.276000 841.890000] /BleedBox [0.000000 0.000000 595.276000 841.890000] /TrimBox [0.000000 0.000000 595.276000 841.890000] /ArtBox [0.000000 0.000000 595.276000 841.890000] /Contents 35 0 R /Rotate 0 /Group << /Type /Group /S /Transparency /CS /DeviceRGB >> /PZ 1 >> endobj 35 0 obj <> stream xnHud'Fd3pN3s%NHݔƯOU&Eʒ@8Cx۾k7>Kۯ_CPmP_oUA} .n ^;1 le{^SuQU F:2;=|/Vs@m[gw7 8p 0MMnFR,93s^d2}G~n}eK~}/lR_q{?1 ř= f [ā=~siErCSN s뇭4Wkapq7{0ME.KYpQVk>5lrbqôC OR#2/nTb 6m(:\.=*CG.BX MY̸`=ɩT]J7.q5R$-(;Iz'Ј" eLCW7N'fʚCv{X> G^tk#13x7I2;P|)f,$w`FHeATRi;z)3Ru8N~KeK#3Eo)9kr3Ay TRbZI||q`#`+p,Q+ȜWZ#.>,XT'a,rrǃsUFaHihyy"%S9w\X1N#k!(J4U,MUQVRt1lS]EО#H&!fnQvAƐ~C"5GւnI'[J/¨$bO[y0Ɛ")UEi ht=sD˴h-1rAA@R xHֆt5E *c9^G쮰2VG-%&ٷ b*`6qpD:"[*D LSҤ0 Q k?GWG_ b5ͺx*-l./0N#o+^%iGLZlq#*J? {Y.ٞfߵJ'h]mC 1hHD6\m#1HP`A6(yaZdž+oECfkH#*7>z-Ts޲V2 Es$ο׻ՄŬuT%.fBwfj\v0Vl,C32i2 ݵn~?A.=X?V(_u<ł-q4eZp슳ǾlY@IU*bX p$߸B]5쒖Yq2'U+7glo!GFCYm'kqU*kv 1q7Jɇ4è*]5( 0%bqM{oBi3׷CGݐ endstream endobj 36 0 obj << /Type /Page /Parent 1 0 R /LastModified (D:20240426123904+02'00') /Resources 2 0 R /MediaBox [0.000000 0.000000 595.276000 841.890000] /CropBox [0.000000 0.000000 595.276000 841.890000] /BleedBox [0.000000 0.000000 595.276000 841.890000] /TrimBox [0.000000 0.000000 595.276000 841.890000] /ArtBox [0.000000 0.000000 595.276000 841.890000] /Contents 37 0 R /Rotate 0 /Group << /Type /Group /S /Transparency /CS /DeviceRGB >> /PZ 1 >> endobj 37 0 obj <> stream x\[}V~CviEZV%Q(o|3$5x[\X͜ng$]3ξOį3?]=}`br^^>~Ÿ=V0?~L}uh_塎}xOчb :kPgZ%ϔsN8v`x{v+vlͻٲjև}Ov5LT?0_8zs0&x6fZi9?ƭ)gq,XY}r/7o7u_ef7OZx;Z32 y?l^msl9\U݆]-foYv]}=ngww .]~6}fcK}b<3k7i zSw]8cUMQ7W3o%;&3li!drYCH}W]dgq뻺7U[9s&L8z}`=Ʒ^qܰ5[ ,&eeMm>EƘ8&B1a&H&y"l0j~9}.G5ɟnv{;)5Zϥm@eBfp}2&8v]YZVzm\m;IS*}+]G #hmPQ9hęH"lt1*t#]ZGǐnAf^/^ulsf Eآ?,n؋W^rwϾ\ [+77]mQ6akQ0 ;*tfuv?;gPlE˒+rMhXx^{Ws|C_ʹցWJdTՐ)1Sv>?t]vAO-y4iS{C-R{U"7domeADĊw}W Hj__ݶ>fꂽk78c{us;p5_ͮ} AS$z'keƾ ](4M=S_hc o6 /ז~D*)Ej ?[x\3mc2)i0UCOkֻ=Zзb[S>\{VVWkmxRNᰠIH[՛Vگ˂Hݦ•7䏴lB&.U3_o-) ZȰ_ glVj,+l)ƫKReb5k?6?gƊbj?Z~^?DDc~Λ#Q:A]=ĩkϙVq͛v~ӏc\ׇQ%MԁGRK[Z5o7N`tXlpv!ֺL0 e9g{kqi RJb`C^?U&zNeΆX@(9gVK"h*Ԃuuɱ (vL4^9xZџ<Pe~ry<;|[.GXWKa]6_>zԕzs ~f jsJ-egˍ ArAeT\ <6 L!;4k3&;a}jp0IkEj]HXAq|5JEX;獤sN+ݲy+SBICr#M=p^!YV*AGhͼϩu{x c_]Щc0\< 5wDhSt@Mv:8@#Ԁv GtVJ?ʁԀU|T6Qz`05@; Jdj@ù t 4΋Dx؀m‰65:`air**χs=r-"1p<>9Z "|hqFr&8(Y"@ jIP<'s&F:#L@&8Bv2e(BrCs eՀQ_32-!;C58 Wf ƞ#182+$O LKLH@X>5e]9F^ =\Z8$"6}j`2:i8S/ a̘dʓًY8!609@#s&BR L'/Γ4cFsw<`)NA ^"3Li >;Jyyl4ęcdyps\A L 1q P zE1_dY YSEb(!3MIY13M `@Ej;RS)Y„٣HH$oMuLĒilJǔ ӻpR!7f؃hPpGcdB?>OcW{l55f'o>;D`h~sv.-TAF۞5=48 rNV4܀D{0jڤ}Sq`Nӯ/㳦dUSa>QU+2ln$T-@պ,+(T-P%9Lx U+v Uk2UK ڧ (T-()b?R91HT|D0@tBd@ T8U[ZZij,QX)dPEP32+#hA\(Tmh2U+Ih]^FP >S㹜gep*ZSC8JsY!A UuTGPCFL D/Tm♪ӈQ.#H5O>1Wh UKTPAJ$ CF^cƤgya SL=OY y2̙Č6(Tm Dbނ)Y 8aPHABe,3.Tm"a =W^4 YBF< )PrSUPPvP塚ddidY 4Ln`yH$9_$ҿΎiJB0$4X`t$uɦPUr,aH" MCjI?gyʖāVz[* Uf<+ gOw ;U8H1W>OOҋN9dۖ-bPUƎhG7GVYio/i>-yR*d&2-K(Y/d5bO>M_i&g͕ɚ!;Uب}ao='_|+2I՟xY ܂YdH^$GAn4Ծ3$%,uyz&<.KK{SڗvPM|[-a1ԾCk_2H% mԾi#Nk_ڴCk|^$}b(/IH,k߸?o>В%oU}i33:/ zڗ`Cڗ@dgR5{BRFs;e^,ǯu̵oOEr=\۬7*׾rM# ,)= @~%PA\Є[Wj_2H`rK2IQ4uJ#k_vQ]Ծ"Ab c HnGwu䤴rK E8+9>L|&,lEĸlکw*KK{H:u %J Ak],ȵ/xd$}u}i{MC\8iID;^j߸8WDоԾi?+kߴJ)CY=,efO* \6GLqtbr<}!-$M. \ (KKu%f/BPҙƖ7,Ln rD\(/ J=)P$߅ԾD"JS&(N<5z /`> /Annots [ 14 0 R 15 0 R 16 0 R 17 0 R 18 0 R 19 0 R 20 0 R ] /PZ 1 >> endobj 39 0 obj <> stream x]]sƕ}ׯ藤ZFˮ,ɊĖ%:٪( Hš(=4@Je*(KEht_碇q%[d< ߼xo_Lw''ƞo`BNo?0O(T7|Ś}uO=~x9<癵VhɬW Xg\(4#Xn\/r(ʲE@+xZ[j=3&F:atpEFKOj;u;%ȅ:9]nJkrrӵN\H̖@nlɰ\8Pj`lX.7R[@ɕX˼RZ\rPN;xn@9Oh\ Q8Ƅ]lZs.1/Dܛ~\c0[k#l1+ Ź'h3p̵aGc̭xm tVʼa/q0fµXlSx@ ay"s&у\s͂Y#Wqȋ=ׂKI`th3dd`2{G\`hF;'YޚA5!m:,&h<")f:Q0͹Q0#Pk'&Uƈ ~'#齑@qU ;kĺ'i/=2aôTfTtd K~a ϵMQh *8HT/µHZmYN^o2s^Kf;@kĐ$#xFF ,5OIP91e%jr`ʣBF8g(FǓ "|MFLFxL@=TyHc!BZ)$! S"0?L`9K%@ mu` Qc6w1GSNRvCn@$8@$tKx;ImYX琙4GwN&c5f\(]?L9OLCVā!E}zJ&,&7X`,=x޲Ps`\ ~~dyǶ/N~"tܷu;qeqVvW,YyvV.M)ۖXwxGvQ)٦iYnXvj/%6l;0w-98mUkdQ_k'cݽ9u8w!&!Q /(e}M9DHE@ S_3!u>! 2RiNE`dRL+"_!{T 2!p5n!BD")"|.B9(hi$0'$\C&?:dl"0v*BsB.B<!ȭISB0ĘTl\y *fsB|Y+ʍ@q].mݓiH c|*B\!"¾z%E"D"VBiL!QsBPʩ!oTsB"|\^!\P!~6]A #FMRP(g"!:!P !.!.k6j*B[VhHԐDSf*BC^B"`B T8 h{gtNE^"@5!A O06T$Nֵ(OEH"@ bҐFr*BvsB!\!{"\CiX!b*BvsB[",bLc9EqԆ"LE=$Thթ!ZIEyKO}cfR c/L|[n,0D |Z6a d_7-3]L*͆ʛ]VۺHӦ,ڎ-͢lXu ^1H#)bl}#&eٔ_ʢi`3z4cլ~S6jŖ\St](WᖃIh<>TepZv$PGڳ1[lQEK]ջ9hzȼ,@.񯃦IhN=MfQ-M,:֬X\ڒ *2F՗ \%4]"$Ty`Zbɟ;e DgT.D)dFd F;ГByރ}Y7ΩiG&-8Pv8մ.(}1ƩtD@T5ľH[vjNоt$07JiGHv $Iv:)iLv:ٗ;J; ;) XO;vFٴ#_K=rZiG`d\ArQ%1BK1iG@,\TFN1H.K;cRB6<մ#@iGlF  % 4ӎ(v^)%B+1AKdr&,GTNyAқc#@셑&TֹiGDĺҫiGpnqiGѝ%8iGkok1q$$(+v8_iG m C3 C6&:CX,v8raӎQS֘[VBFшf^Ob{mtQ P!T'^z-J;칞xӎ@c{- SsݤIsJO;+(TvN9 ^B>O;ÒbOw [?9mB hI bvyCfђ#@ ~ U4vLcI4Ir3,U5qҎy#Snv˅ 0)U߯#%9XsƮ5 OݤqųgY;`]/m]T#/Gl+Im`2(L9nwMy-uag;.\k!VUzۺj56)r\4Cح{*Ԩ[aBƭ8aۺ_>c_xxɳ{ [7]㢪{Yl^_G("C:'|&FIE9?ƲG@,WryYtN:[~~ X8gBcY 'k˒\Usv[~sCo: n~o܈M.%plĶ.;9VoBfy|3(ٻ={9EFCYݒv->|ݳw}n}G{ƝsSw]ՆQo-~p&!ėjo^'%I*>+ܳ}&9:1췫w>0ϯ7 iQ|gdӕͶ[-9 phE{]4[Wm NkMV$W%?/YkeݬNjUѶ7"hUx |pm1$`u?k/iyUbYQ+V6&=pbb%}"t^1[u*A棇~U{D/Lf;|@Ki]\u:x+I|\]nyHۛ,%12Oz%2kPS]I m+*8)(ÝTClX8 c(9916]o["f3/H1ruΪryvuł l2޴-k|Ua{HaPJhg=kM%oRCC`(6X+ߟtsʷ۲Hfٖ*(݇*O5՟<ɛz>+QPA" sDC*s92Kےz< gLc8Sb8VQtvl[m4]p!۔ Q]mw7¿]v^UԤAm 쉠ڲ-$O XZeK*maҰTmiilyH LLg$E#K1^o.~&M`f {-+tĺh*zB2K 93}$SC$S'V.Kk|u :7jӇ&zcomV7[/>M>{IЗѽ]q>7IAZTt^@Yi2ONf˾te|t@ ;8?WdNuKVGpǏpG^e(.%V,Գۭޭ_ߖMu2e$ME"{4gݷ~~:&*{VM[rt nqYm=u}D'<%ث/j/S>_OJAݜXqI.e?m"O,&G ?KI:*;bꖟ'd fu0l6+ag8c> /Annots [ 21 0 R 22 0 R 23 0 R ] /PZ 1 >> endobj 41 0 obj <> stream xZ[S@~WGu/Bڪvj:xy dXF:v%MlH Nd,߹}g#cu#`>pqN-GAH]o|l'/h~c?38P {t x_N5ufu`&6{^AMFM =$! 1(XFsN84Zp8vafG6@\nm]AK"œfnvLB}ueuH2 4/|PlM3df>dhREwUʑ գ™:u (wé|ɮNsI-t:06V H=&K}_ ,'FNg!|,YƄZ3 -6IWnޚCGgs g!]k*4ޘrqAbؗave^TicU* npiшÓ<4Itpl C, ޯTVB[d #۲ 4tO1N{$A:[1 YڊtpQ\2a}JŽSR}hdb4Mɣװ] S'V)BܛHL6Fsܰzq䞋Px.쇱x@6ăd#8xWv:"|7e )[[F#ŋjh8fNXԝNy0fG|TRX_hH(V$g-f61tׅkF~_+ P @0r6İa.[@^?ӕQ}JRr^rU$ׁN[v*T:#*ݻ'{> /Annots [ 24 0 R 25 0 R 26 0 R 27 0 R ] /PZ 1 >> endobj 43 0 obj <> stream xYMsGW`%*$)bˎ)@fzZ1 D.Y[o{zuD&˝8rO~^Ǟkųǎg/[MܽGxX1w?L㛹xwqSj7տ}ŧwo3sty]}>sv#66,w0,V7O`KEu9FbΧ8ɞ{q/Ie}L~ 2/dteQ2͇sc7}ݹ!}L<Х_v_y…C' qz-N;KNwk7?{ݫI7Om*ʲ)'B̛zb2_c=1s͎o!*wA7R|pvt|￵q n}|{%3pu;5XΜ/ŦE7ZgO=1?(3KfʳI[ %w.PJ")Xk*IS#.>&x\%Q*9R ,s 19WX̢7٠9.ɧk >%૬Bn`,H)7%eK*!| +u%F@ArFMo8)U6ek `+$* MIMbP"&J&\A_3PREP @X )HLLI\1&55`"5 * ^,BJ C`{gAmAj"J;eA $M/9*6h #0̒S2GX!S/<HٜEcu*P.#FRe,1nU}d2 GQ2&j1LDUiZ3eʉ_SbDl!X1T(\d1Q#1lQwȷjj!{bU"l Z E Vf,DM}w˘q`i9x-ŀ`8"MvH Wb\O#Svނ!I92׈p6/` rӓk-JLeBZ 3S0H~FQ1]!S0Zx\ڕG P3q1CHn@ОZC1# ͧ7nS:mF-j$MKƍ`H }O018USR,֑4+0S$^m,ة cd&h_ֆ+WkFm.1)x_l1=DlZ-P9񀱻uue Tw)=];p~rz>sn!x[Xn k%}tjK(SHhLٞ=_n=vntǻo`> endobj 3 0 obj <> endobj 4 0 obj <> endobj 13 0 obj <> endobj 44 0 obj <> /Resources <> /Font <> /ExtGState <> /ProcSet [/PDF /Text /ImageB /ImageC /ImageI ] >> /Filter /FlateDecode /Length 848 >> stream xWmO0^c$H (똆AIC|J(ՠemIªل׹Gdw7>9<GkDžaW$<"H2|R(29:9$^-e>..y.Gd:|VCd` ')ɮB(TEҒ %% E֙ J,$BDO&D>MH0-6=C.h&CfR\ X+b :Nic*k+ p.}&xs|"8 n,v )W-6o=߸hNftK:M[ۀr!e\KeAky$RP<⺍pxup8>H  M{qI3_w,縲eGfNՑmna.hȓjYU,b\2OuyZ6#sC͚3gkriӲ ly#4]kDfu |w*lm O镸080iIsӵһ%7/i\XJ.̚5K5jM9aq'wqh%Q*i gyQ(p]5'CԫkSuRCln_*9{.+|FAqp-Pg*O hsRՎSJ&`1U$GBHB-K5NюG~?Rh#%SkC3a-r"7αը $O+ o endstream endobj 51 0 obj <> /Resources <> /Font <> /ProcSet [/PDF /Text /ImageB /ImageC /ImageI ] >> /Filter /FlateDecode /Length 220 >> stream x]M0EԅIтUqEڅ̿7.:Ãۼ{?bb_"YiFgTT&IF |Sk=(PB{U!Z]?s{7mCwoTbV DH)iRHK 4 A&J0;*UaVj&T]Y-v|OɄzUx5>w I endstream endobj 50 0 obj <> endobj 49 0 obj <> endobj 56 0 obj [250 0 0 0 0 0 0 0 0 0 0 564 0 333 250 0 500 500 500 500 500 0 500 500 500 500 0 0 0 0 0 0 921 0 0 0 722 611 556 722 722 0 0 0 0 889 0 0 556 0 667 556 0 0 0 0 0 0 611 0 0 0 0 0 0 444 500 444 500 444 0 0 500 278 0 500 278 778 500 500 500 0 333 389 278 500 500 722 500 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 333 ] endobj 55 0 obj <> endobj 48 0 obj <> stream x  Om7^ Oa endstream endobj 57 0 obj <> stream x nH@o endstream endobj 47 0 obj <> stream JFIF``C    $.' ",#(7),01444'9=82<.342C  2!!22222222222222222222222222222222222222222222222222" }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( m{HV*ڝ 2֍sD$;k]-j** jmZކ6PϷXkW״y,H$c``qW_Wx4pYd]pI"TnϿD1Vn57N]KEgi70n63# :*Zޡyڬ4:Гp vFJ{m龖u_!Fxgnz犯6cjP <,08 - bE^Z7wmfON4%pJ<H%f\OnMowC۾ǽG6<_jx0&s7kvߙokVkY~nn䲺k[X0eXuV ~ILA+G#I(D8qc=>J'}77h/Uknmkkb 0yHw/6@2nY*pMzU3%ėڌʻe/9I>OS_zwqlTM$1!vzڥʺy22eg{/㱷EgX\?lJ8cU4I #|K3G|T{ƿZZunTpCp*H1S0I\։r,f ěsR>hJq:Z+ -kP[ '̀ 8B޻F9fB<8D>hݴ5NDn+E說uZk6(95Gyd , 9kVh驖cdex[O!U'}me}SZwТ5;hMΌR ϲp"5iOW|LS d {u*mMow4Z4baIXcnf>L«hIc}h4lHg'R*uٽ~ocVʳէ{~`HdS!r+3Cm{TWx24VgQccm{u"=ŰNy'&U Eٻ~-lNr֨WIѥ;W>z+YT3*RWi4׫8ȗĚ̐Zrо ~EO XOԒM]mllͭ[#l%IMIikV"v''EPG9@``n^s _vbWe[3ImjK}\iY >}Ac1GI]VkזׂMKsn!rK2@ێ=xku{MJ8EDR.v)_KIkz>M +mv_k2sRj#$d>Zl;5i!)70 :^v?Rnm{ZnkYWzXiqVj a idzI cK>n[}鹭Eb6q6wXy۰Mqjk Vy4Qotdtf߯QRSmZmB;iI $l3gVf]&k|QlaB$&pL#oN55&!b+rVvپz]ڽivI:@$Yv&F'>m͵ 3D[pe=OqIњWȨi\iQX"v:k"H)2Hb9$rN3[3(;HUY^љ] ʇ O|k%ՐVfrkzxшLn\]:Jq|JǶkRwooYRm,ѵӱYWz\bIYؑ'}(n^EEDzM"5u}f7/vkX$*8!YbEi" H򤌌3\'m9CqqJֲ: @KgɜL*A}gK$խS/+mEaEjw -ӬfY< ~5$!?ɫG 0xXemH=y*^KFW+]WA Xrڨktk@¼eeی;g5O]M絷ZD2m1|prQ}]DTӌ%%{{Ym(eB$18 d>i:v N2FGҥQ_r劥z/=4\ې&8Nx8Ts~V=Z X'g"YVwqw6q#$ӄ#%0U8KHi$7WSЩȧU ZhQRYv~RiS ((((m6d պᅾ[UM#zͽЬon>$78ǝ6#܎k G^5ZsUZzYjrik$XrIj[)R?}馕mm43|\ ێgH{ JqӗFk[]-4Iq)J,iAD['ciHF:VZ<Li>sBz'}֤pK{ ۩3B<EŜR*>H?J̩ay'rXP 's29cM.+j)CE*B VgY\fY.z e(FjW%# tΜYZs>߱IgԵkm."ٖ7qy$lgzun>%u?JjI&:LԖ:=: $qi =ңBm N[Wߦ~E=t>?Q7H,ඞh.4$䁏CYzT6O'$cuW3~V,ZSQ+͓&#.mjDL$hqQ (I_ZnSGMHᷓE2X\m3 vWF4 0[c,=֧mt- Yy5B TaIۖ6׽yEU Zb}?nTvpXbR]I䜚59.NJ0{rvZ5Oyu wmm<=XγfUıLoeDIp9'$ ~bvh`^Q\n3j:Ykd$h"0x侖ad̛Fߘ`Zzٻ<v,=:E: !a,,]ds9j4Vvc,=iJ[J[e_M\vAjϚ9%>- KwJܗGQ[JnLr2@ 7\ӊ^).P{sIavzƕi-vtأO k-od@_rpGo?Kb{#vDbz?[}&M37 i<$t9׭ZAIK=TZוOVe;l?ʹ^?*J`EKifXҪkOՉʭ2_7o+a})!7&t2U=>-[E5w<7QGcVz=iX:i t'ҫ/rY.+ 1ӌө7oLε |$m[׺h&$wX6+ $tVN{w 5HaҭW;嶇ly (((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((( endstream endobj 46 0 obj <> stream x  Om783  endstream endobj 58 0 obj <> stream x nH@paX endstream endobj 45 0 obj <> stream JFIF``C    $.' ",#(7),01444'9=82<.342C  2!!22222222222222222222222222222222222222222222222222bb" }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( *kZ= )՘W5mZx?sS)(rbzz.-+E_|dF>g?qZP ]3N'K:?ƸT/.\$s1c 'j9W᭏=Mrķsݓ@aGrZ}{R}NՋHf?^d!,.@#VnZ)BJPG i6ב9O?0H\kǝףG1>X;} ExM_@eZ}H2Bo_U a1Jr˺-aUL cZݫ L7YSG/k?oo\jSѫV]֙宙>bx.2)YWN/XޑxVRr{W\֡p~Z7gS憌#ˌ5JOkT{Y$9$5b'JAI a}%hT(((kH0zVBEY[RI(GJ?zӉ[?kFniE?D;o l_DP^Xž "Lh?g |{עW|mIW̗ɏL,WQCz-Wv\@He@єRWWTV.⤂( ( ( ( ( ( ( ( ( ( ( ( ( ziSs('*:e>#j\!eG9_Ɍ-/S#N_GxA'4?2+><(niv%Lp?aG2_Iѽ~kNe>XՂ (((((F`Y I=c9ũՍ0}E $=M ||?hjz#59½OC+oEQEQEQEQEQEQEQEQEQEQEQEQEW;65(jnm;<>/sW~ʯT4bXZJy UEYk (;QEIaEPEPYֳmX5,x0yvmwĶZDH[>X>Uծ{ƹ|EQPz^*ϚzG<\7.7y^V/ԯe}Hr}~SZs;p } J*:ӟ4lNHcfF q*<%s] o,z'eд ( ( ( ( ( ( ( ( ( ( ( ( ( +h[TělOSa )CV &8ş#im ҺkIT׆>+)lݶ~^ s_QJT~΢7ȩk>l]GȮϟekYx^=+Spߊ\5l5*F\u|+)[˧{%{|=?Z5o^݆1i~r?5Q]r4ڻUfԜ?t=*ߔ<3cVoĒkN_Wr>ʍ?g+P(((((((((((((߄a~*^Ù-e?އ?_5/e(H+ωOMUM^%t ;{cb3 cuV`k8 s\j=KtquV s^d|':d4sYP:մg:M訄y+E3Q@rLPw܁ޕ#Iifu˫梹k j%#a[a{vX5 <]/.Ѱ(vO},: q̧0cw>g`p IQ^QQ@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@g..-55\%ʯwG^ Yٵ;V's[ӭ}]U-5;Gr`:'KG9k!W]򥾣Z1_k|CJ}9[ϗo?לj^n4學W/#{l[%вEK]Ha*AsΖQ^ZNƿsҎq,: oY杦sZ/~u2IO~?.e_XsX?k*?2G}%pƹ&=K!..;QGonZ/ i4(|<կ'Ov/`OW (((((((((((((((<2"V`)\>|v08 Z( ( ( +7YcSFڇc65Mťvnɕ/4;P+_Nc,b=MNQى/ts)QПkRú.A,`aѣE?MD : nލPcϢ5-AAEPExK֧O`-a9?iKa9$osN(0(((((((((((z+qBԃTs\q [3kG|?wwXEu2դB)Mj὜6R~j6dTFLr@ bWW9]،EJxYۡÇNxxt8+z$oR>V>VNj|=i1}j$|$|t7WDx%y"E:9/ \ PI4A({U~ Z;u՛!/+s%K1 @A#k>X;CUB]TU88s-wrpq~j ;ƻnŧ H\4`N΀XzYTs)ՔtI)bH5K ,RFQ2l{&o~,fl;|Aj~)XeزE PsʁV<mw[iOl#dP ޠnNsZBp7i}pI$Js6qnD1ykZ<:ڹcԓ'T&*mNYQT18J^)jkoEe [xZfm,Y@Ԍ m:/Ŧ<.مP;zV?~6ݶy ޹U9B&TeOI껛V 4jTFN `Ӯr+GP%_VFBI( Z|%]Z-C;bn8 GB+v-A𦩨뗷r2z8JrSV۶2ԋ$~д}14Ni^#K! D, O@NzWH%Kkw* B2O%{w?ABӯ{i Ȇ(@3d凄\ݕLqz>-6y jp>?|aP>?9j? C|XehmQ (8C\F|µ 'kt♜k OkhS bSyp0Y[\!<yj3EqO $R(du9 Ba"։.co2g夑8?s׍ëw17Ṿ; Q\:}$_;{=SOGXUp\*%7?g۰sy9yF hYj ۙrT𮓩hRi_b8cpiZ\U4JmEp_ u+ Kor'8LI1]aV7ڕER kQEQEQEQEQEQEQEQEQEUMVO+G?)V覝Տ#m  hVZTo ?ٮX>94 iW1bOy'yEt Tu9u 6un/ ?FrDeQ`~xk^ \v-kG"NZퟝLWQJ8:nאU쒷y^d)Ze1ijd`u?zYC/&wnF1ֽrj5ǚM᫏"lB֪$9YK=2 *ޑ"lb4J-V%)lXÌ޽Onkӄgc$KymhfkuRn3[KjIoXԱ?^WUE%^ܖ_ N%c˼]!-ge2X0EzMImnCDd{ EMJQV—$/U) %qm"HAg{_ĈUڊJ 5%r6]5a)4$UM9 ៥kMxWubh0?,~:~5TVZӎ3ZK[_|AYk%ڬA OL~|5YP1cBgz 3s)+n ?+'ʟٞmc ,\ӱ3@{ d+ːJёé=qz:)iE-WQf y`JE;!4c ~c[L?= $v$7>#^&Yk%X,O$U > endobj 60 0 obj [250 ] endobj 59 0 obj <> endobj 53 0 obj <> stream JFIF``C    $.' ",#(7),01444'9=82<.342C  2!!22222222222222222222222222222222222222222222222222" }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( m{HV*ڝ 2֍sD$;k]-j** jmZކ6PϷXkW״y,H$c``qW_Wx4pYd]pI"TnϿD1Vn57N]KEgi70n63# :*Zޡyڬ4:Гp vFJ{m龖u_!Fxgnz犯6cjP <,08 - bE^Z7wmfON4%pJ<H%f\OnMowC۾ǽG6<_jx0&s7kvߙokVkY~nn䲺k[X0eXuV ~ILA+G#I(D8qc=>J'}77h/Uknmkkb 0yHw/6@2nY*pMzU3%ėڌʻe/9I>OS_zwqlTM$1!vzڥʺy22eg{/㱷EgX\?lJ8cU4I #|K3G|T{ƿZZunTpCp*H1S0I\։r,f ěsR>hJq:Z+ -kP[ '̀ 8B޻F9fB<8D>hݴ5NDn+E說uZk6(95Gyd , 9kVh驖cdex[O!U'}me}SZwТ5;hMΌR ϲp"5iOW|LS d {u*mMow4Z4baIXcnf>L«hIc}h4lHg'R*uٽ~ocVʳէ{~`HdS!r+3Cm{TWx24VgQccm{u"=ŰNy'&U Eٻ~-lNr֨WIѥ;W>z+YT3*RWi4׫8ȗĚ̐Zrо ~EO XOԒM]mllͭ[#l%IMIikV"v''EPG9@``n^s _vbWe[3ImjK}\iY >}Ac1GI]VkזׂMKsn!rK2@ێ=xku{MJ8EDR.v)_KIkz>M +mv_k2sRj#$d>Zl;5i!)70 :^v?Rnm{ZnkYWzXiqVj a idzI cK>n[}鹭Eb6q6wXy۰Mqjk Vy4Qotdtf߯QRSmZmB;iI $l3gVf]&k|QlaB$&pL#oN55&!b+rVvپz]ڽivI:@$Yv&F'>m͵ 3D[pe=OqIњWȨi\iQX"v:k"H)2Hb9$rN3[3(;HUY^љ] ʇ O|k%ՐVfrkzxшLn\]:Jq|JǶkRwooYRm,ѵӱYWz\bIYؑ'}(n^EEDzM"5u}f7/vkX$*8!YbEi" H򤌌3\'m9CqqJֲ: @KgɜL*A}gK$խS/+mEaEjw -ӬfY< ~5$!?ɫG 0xXemH=y*^KFW+]WA Xrڨktk@¼eeی;g5O]M絷ZD2m1|prQ}]DTӌ%%{{Ym(eB$18 d>i:v N2FGҥQ_r劥z/=4\ې&8Nx8Ts~V=Z X'g"YVwqw6q#$ӄ#%0U8KHi$7WSЩȧU ZhQRYv~RiS ((((m6d պᅾ[UM#zͽЬon>$78ǝ6#܎k G^5ZsUZzYjrik$XrIj[)R?}馕mm43|\ ێgH{ JqӗFk[]-4Iq)J,iAD['ciHF:VZ<Li>sBz'}֤pK{ ۩3B<EŜR*>H?J̩ay'rXP 's29cM.+j)CE*B VgY\fY.z e(FjW%# tΜYZs>߱IgԵkm."ٖ7qy$lgzun>%u?JjI&:LԖ:=: $qi =ңBm N[Wߦ~E=t>?Q7H,ඞh.4$䁏CYzT6O'$cuW3~V,ZSQ+͓&#.mjDL$hqQ (I_ZnSGMHᷓE2X\m3 vWF4 0[c,=֧mt- Yy5B TaIۖ6׽yEU Zb}?nTvpXbR]I䜚59.NJ0{rvZ5Oyu wmm<=XγfUıLoeDIp9'$ ~bvh`^Q\n3j:Ykd$h"0x侖ad̛Fߘ`Zzٻ<v,=:E: !a,,]ds9j4Vvc,=iJ[J[e_M\vAjϚ9%>- KwJܗGQ[JnLr2@ 7\ӊ^).P{sIavzƕi-vtأO k-od@_rpGo?Kb{#vDbz?[}&M37 i<$t9׭ZAIK=TZוOVe;l?ʹ^?*J`EKifXҪkOՉʭ2_7o+a})!7&t2U=>-[E5w<7QGcVz=iX:i t'ҫ/rY.+ 1ӌө7oLε |$m[׺h&$wX6+ $tVN{w 5HaҭW;嶇ly (((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((((( endstream endobj 52 0 obj <> stream JFIF``C    $.' ",#(7),01444'9=82<.342C  2!!22222222222222222222222222222222222222222222222222bb" }!1AQa"q2#BR$3br %&'()*456789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz w!1AQaq"2B #3Rbr $4%&'()*56789:CDEFGHIJSTUVWXYZcdefghijstuvwxyz ?( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( *kZ= )՘W5mZx?sS)(rbzz.-+E_|dF>g?qZP ]3N'K:?ƸT/.\$s1c 'j9W᭏=Mrķsݓ@aGrZ}{R}NՋHf?^d!,.@#VnZ)BJPG i6ב9O?0H\kǝףG1>X;} ExM_@eZ}H2Bo_U a1Jr˺-aUL cZݫ L7YSG/k?oo\jSѫV]֙宙>bx.2)YWN/XޑxVRr{W\֡p~Z7gS憌#ˌ5JOkT{Y$9$5b'JAI a}%hT(((kH0zVBEY[RI(GJ?zӉ[?kFniE?D;o l_DP^Xž "Lh?g |{עW|mIW̗ɏL,WQCz-Wv\@He@єRWWTV.⤂( ( ( ( ( ( ( ( ( ( ( ( ( ziSs('*:e>#j\!eG9_Ɍ-/S#N_GxA'4?2+><(niv%Lp?aG2_Iѽ~kNe>XՂ (((((F`Y I=c9ũՍ0}E $=M ||?hjz#59½OC+oEQEQEQEQEQEQEQEQEQEQEQEQEW;65(jnm;<>/sW~ʯT4bXZJy UEYk (;QEIaEPEPYֳmX5,x0yvmwĶZDH[>X>Uծ{ƹ|EQPz^*ϚzG<\7.7y^V/ԯe}Hr}~SZs;p } J*:ӟ4lNHcfF q*<%s] o,z'eд ( ( ( ( ( ( ( ( ( ( ( ( ( +h[TělOSa )CV &8ş#im ҺkIT׆>+)lݶ~^ s_QJT~΢7ȩk>l]GȮϟekYx^=+Spߊ\5l5*F\u|+)[˧{%{|=?Z5o^݆1i~r?5Q]r4ڻUfԜ?t=*ߔ<3cVoĒkN_Wr>ʍ?g+P(((((((((((((߄a~*^Ù-e?އ?_5/e(H+ωOMUM^%t ;{cb3 cuV`k8 s\j=KtquV s^d|':d4sYP:մg:M訄y+E3Q@rLPw܁ޕ#Iifu˫梹k j%#a[a{vX5 <]/.Ѱ(vO},: q̧0cw>g`p IQ^QQ@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@Q@g..-55\%ʯwG^ Yٵ;V's[ӭ}]U-5;Gr`:'KG9k!W]򥾣Z1_k|CJ}9[ϗo?לj^n4學W/#{l[%вEK]Ha*AsΖQ^ZNƿsҎq,: oY杦sZ/~u2IO~?.e_XsX?k*?2G}%pƹ&=K!..;QGonZ/ i4(|<կ'Ov/`OW (((((((((((((((<2"V`)\>|v08 Z( ( ( +7YcSFڇc65Mťvnɕ/4;P+_Nc,b=MNQى/ts)QПkRú.A,`aѣE?MD : nލPcϢ5-AAEPExK֧O`-a9?iKa9$osN(0(((((((((((z+qBԃTs\q [3kG|?wwXEu2դB)Mj὜6R~j6dTFLr@ bWW9]،EJxYۡÇNxxt8+z$oR>V>VNj|=i1}j$|$|t7WDx%y"E:9/ \ PI4A({U~ Z;u՛!/+s%K1 @A#k>X;CUB]TU88s-wrpq~j ;ƻnŧ H\4`N΀XzYTs)ՔtI)bH5K ,RFQ2l{&o~,fl;|Aj~)XeزE PsʁV<mw[iOl#dP ޠnNsZBp7i}pI$Js6qnD1ykZ<:ڹcԓ'T&*mNYQT18J^)jkoEe [xZfm,Y@Ԍ m:/Ŧ<.مP;zV?~6ݶy ޹U9B&TeOI껛V 4jTFN `Ӯr+GP%_VFBI( Z|%]Z-C;bn8 GB+v-A𦩨뗷r2z8JrSV۶2ԋ$~д}14Ni^#K! D, O@NzWH%Kkw* B2O%{w?ABӯ{i Ȇ(@3d凄\ݕLqz>-6y jp>?|aP>?9j? C|XehmQ (8C\F|µ 'kt♜k OkhS bSyp0Y[\!<yj3EqO $R(du9 Ba"։.co2g夑8?s׍ëw17Ṿ; Q\:}$_;{=SOGXUp\*%7?g۰sy9yF hYj ۙrT𮓩hRi_b8cpiZ\U4JmEp_ u+ Kor'8LI1]aV7ڕER kQEQEQEQEQEQEQEQEQEUMVO+G?)V覝Տ#m  hVZTo ?ٮX>94 iW1bOy'yEt Tu9u 6un/ ?FrDeQ`~xk^ \v-kG"NZퟝLWQJ8:nאU쒷y^d)Ze1ijd`u?zYC/&wnF1ֽrj5ǚM᫏"lB֪$9YK=2 *ޑ"lb4J-V%)lXÌ޽Onkӄgc$KymhfkuRn3[KjIoXԱ?^WUE%^ܖ_ N%c˼]!-ge2X0EzMImnCDd{ EMJQV—$/U) %qm"HAg{_ĈUڊJ 5%r6]5a)4$UM9 ៥kMxWubh0?,~:~5TVZӎ3ZK[_|AYk%ڬA OL~|5YP1cBgz 3s)+n ?+'ʟٞmc ,\ӱ3@{ d+ːJёé=qz:)iE-WQf y`JE;!4c ~c[L?= $v$7>#^&Yk%X,O$U > /XObject <> >> endobj 5 0 obj <> /H /I>> endobj 6 0 obj <> /H /I>> endobj 7 0 obj <> /H /I>> endobj 8 0 obj <> /H /I>> endobj 9 0 obj <> /H /I>> endobj 10 0 obj <> /H /I>> endobj 11 0 obj <> /H /I>> endobj 12 0 obj <> /H /I>> endobj 14 0 obj <> /H /I>> endobj 15 0 obj <> /H /I>> endobj 16 0 obj <> /H /I>> endobj 17 0 obj <> /H /I>> endobj 18 0 obj <> /H /I>> endobj 19 0 obj <> /H /I>> endobj 20 0 obj <> /H /I>> endobj 21 0 obj <> /H /I>> endobj 22 0 obj <> /H /I>> endobj 23 0 obj <> /H /I>> endobj 24 0 obj <> /H /I>> endobj 25 0 obj <> /H /I>> endobj 26 0 obj <> /H /I>> endobj 27 0 obj <> /H /I>> endobj 61 0 obj << /Title (Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo s ADC DS-1062) /Author (Daiichi Sankyo) /Subject (Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo s ADC DS-1062) /Creator (TCPDF) /Producer (TCPDF 6.5.0 \(http://www.tcpdf.org\)) /CreationDate (D:20240426123904+02'00') /ModDate (D:20240426123904+02'00') /Trapped /False >> endobj 62 0 obj << /Type /Metadata /Subtype /XML /Length 4919 >> stream application/pdf Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo’s ADC DS-1062 Daiichi Sankyo Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo’s ADC DS-1062 2024-04-26T12:39:04+02:00 TCPDF 2024-04-26T12:39:04+02:00 2024-04-26T12:39:04+02:00 TCPDF 6.5.0 (http://www.tcpdf.org) uuid:6be0a672-52de-55d9-12a1-6f57492b9238 uuid:6be0a672-52de-55d9-12a1-6f57492b9238 http://ns.adobe.com/pdf/1.3/ pdf Adobe PDF Schema internal Adobe PDF Schema InstanceID URI http://ns.adobe.com/xap/1.0/mm/ xmpMM XMP Media Management Schema internal UUID based identifier for specific incarnation of a document InstanceID URI http://www.aiim.org/pdfa/ns/id/ pdfaid PDF/A ID Schema internal Part of PDF/A standard part Integer internal Amendment of PDF/A standard amd Text internal Conformance level of PDF/A standard conformance Text endstream endobj 63 0 obj << /Type /Catalog /Version /1.7 /Pages 1 0 R /Names << >> /ViewerPreferences << /Direction /L2R >> /PageLayout /SinglePage /PageMode /UseNone /OpenAction [28 0 R /FitH null] /Metadata 62 0 R >> endobj xref 0 64 0000000000 65535 f 0000026524 00000 n 0000063779 00000 n 0000026633 00000 n 0000026739 00000 n 0000063930 00000 n 0000064183 00000 n 0000064482 00000 n 0000064689 00000 n 0000064896 00000 n 0000065103 00000 n 0000065311 00000 n 0000065590 00000 n 0000026850 00000 n 0000065890 00000 n 0000066187 00000 n 0000066488 00000 n 0000066787 00000 n 0000067024 00000 n 0000067258 00000 n 0000067484 00000 n 0000067731 00000 n 0000067971 00000 n 0000068218 00000 n 0000068425 00000 n 0000068634 00000 n 0000068843 00000 n 0000069240 00000 n 0000000015 00000 n 0000000485 00000 n 0000001730 00000 n 0000002225 00000 n 0000005053 00000 n 0000005531 00000 n 0000009472 00000 n 0000009924 00000 n 0000012300 00000 n 0000012752 00000 n 0000017419 00000 n 0000017932 00000 n 0000022943 00000 n 0000023428 00000 n 0000024473 00000 n 0000024965 00000 n 0000026965 00000 n 0000038649 00000 n 0000037856 00000 n 0000030186 00000 n 0000029626 00000 n 0000028773 00000 n 0000028717 00000 n 0000028185 00000 n 0000055279 00000 n 0000047609 00000 n 0000047149 00000 n 0000029374 00000 n 0000028959 00000 n 0000029933 00000 n 0000038337 00000 n 0000047357 00000 n 0000047334 00000 n 0000069458 00000 n 0000070259 00000 n 0000075261 00000 n trailer << /Size 64 /Root 63 0 R /Info 61 0 R /ID [ <6be0a67252de55d912a16f57492b9238> <6be0a67252de55d912a16f57492b9238> ] >> startxref 75471 %%EOF

Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo’s ADC DS-1062

Company

• Agreement represents second collaboration between Daiichi Sankyo and AstraZeneca for a Daiichi Sankyo DXd antibody drug conjugate (ADC)

• AstraZeneca to pay Daiichi Sankyo up to $6 billion in total consideration, including a $1 billion upfront payment and up to an additional $5 billion contingent upon achievement of future regulatory and sales milestones

 

Tokyo, Munich and Basking Ridge, NJ – (July 27, 2020) – Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today that it has entered into a global development and commercialization agreement with AstraZeneca (LSE, STO, NYSE: AZN) for Daiichi Sankyo’s DS-1062, a TROP2 directed DXd antibody drug conjugate (ADC), currently in phase 1 clinical development for non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC).

Daiichi Sankyo and AstraZeneca will jointly develop and commercialize DS-1062 worldwide, except in Japan where Daiichi Sankyo will maintain exclusive rights. Daiichi Sankyo will manufacture and supply DS-1062.

This agreement represents the second global ADC collaboration between the two companies following a similar agreement in March 2019 for Daiichi Sankyo’s ENHERTU®, a HER2 directed DXd ADC.

“DS-1062, one of our lead DXd ADCs that will form a pillar of our next mid-term business plan, has the potential to become a best-in-class TROP2 ADC in multiple tumors, including lung and breast cancers,” said Sunao Manabe, Representative Director, President and CEO of Daiichi Sankyo Company, Limited. “This new strategic collaboration with AstraZeneca, a company with extensive experience and significant expertise in the global oncology business, will enable us to deliver DS-1062 to more patients around the world as quickly as possible. As we have done with ENHERTU, we will jointly design and implement strategies to maximize the value of DS-1062.”

“We see significant potential in this antibody drug conjugate in lung as well as in breast and other cancers that commonly express TROP2,” said Pascal Soriot, Chief Executive Officer, AstraZeneca. “We are delighted to enter this new collaboration with Daiichi Sankyo and to build on the successful launch of ENHERTU to further expand our pipeline and leadership in oncology. We now have six potential blockbusters in oncology with more to come in our early and late pipelines.”  

Financial Terms
Under the terms of the agreement, AstraZeneca will pay Daiichi Sankyo an upfront payment of $1 billion,  of which $350 million is due upon execution, $325 million after 12 months and $325 million after 24 months. Contingent payments of up to $5 billion include $1 billion for achievement of future regulatory milestones, and $4 billion for sales-related milestones. Total payments under the agreement have the potential to reach up to $6 billion.

Daiichi Sankyo and AstraZeneca will share equally development and commercialization costs as well as profits from DS-1062 worldwide, except for Japan. Daiichi Sankyo is expected to book sales in U.S., certain countries in Europe, and certain other markets where Daiichi Sankyo has affiliates. AstraZeneca is expected to book sales in other markets worldwide, including China, Australia, Canada and Russia.

The upfront payment and regulatory milestones will be booked as revenue over the period in which Daiichi Sankyo has contractual performance obligations under this collaboration. Impact on Daiichi Sankyo’s consolidated financials for fiscal year ending March 31, 2021 will be announced at an appropriate time in the future. The collaboration is expected to enhance the corporate and shareholder value for Daiichi Sankyo over the mid- to long-term.

About TROP2
TROP2 (trophoblast cell-surface antigen 2) is a transmembrane glycoprotein that is overexpressed in many cancers including up to 80 percent of patients with triple negative breast cancer.[i],[ii] High TROP2 expression also has been identified in a majority of NSCLCs.[iii] Research indicates that high TROP2 expression is associated with cancer cell growth and proliferation and poor patient survival.[iv] TROP2 is recognized as a promising molecular target for therapeutic development in various cancers.4

About DS-1062
DS-1062, a TROP2 directed ADC, is one of three lead DXd ADCs in the oncology pipeline of Daiichi Sankyo.

ADCs are targeted cancer medicines that deliver cytotoxic chemotherapy (“payload”) to cancer cells via a linker attached to a monoclonal antibody that binds to a specific target expressed on cancer cells. Designed using Daiichi Sankyo’s proprietary DXd ADC technology, DS-1062 is comprised of a humanized anti-TROP2 monoclonal antibody attached to a topoisomerase I inhibitor payload by a tetrapeptide-based linker with a customized drug-to-antibody ratio (DAR) of four to optimize the benefit-risk ratio for the intended patient population.

Preclinical studies have demonstrated that DS-1062 selectively binds to the TROP2 receptor on the surface of a tumor cell. It is proposed that DS-1062 is then internalized into the cancer cell where lysosomal enzymes break down the tetrapeptide-based linker and release the DXd payload.

DS-1062 is currently being evaluated in a phase 1 trial in patients with advanced solid tumors that are refractory to or relapsed from standard treatment or for whom no standard treatment is available. The study is currently enrolling patients with unresectable advanced NSCLC and unresectable/advanced or metastatic TNBC.

DS-1062 is an investigational agent that has not been approved for any indication in any country. Safety and efficacy have not been established.

About the Collaboration between AstraZeneca and Daiichi Sankyo
Daiichi Sankyo and AstraZeneca entered into a global collaboration to jointly develop and commercialize ENHERTU (a HER2 directed ADC) in March 2019, and DS-1062 (a TROP2 directed ADC) in July 2020, except in Japan where Daiichi Sankyo maintains exclusive rights. Daiichi Sankyo is responsible for manufacturing and supply of ENHERTU and DS-1062.

ENHERTU (trastuzumab deruxtecan; fam-trastuzumab deruxtecan-nxki in the U.S. only) currently is approved in the U.S. and Japan for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who received two or more prior anti-HER2-based regimens based on the DESTINY-Breast01 trial, and is under accelerated assessment in the EU for a similar potential indication.

U.S. FDA-Approved Indication for ENHERTU
ENHERTU is a HER2 directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.

This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

 

WARNING: INTERSTITIAL LUNG DISEASE and EMBRYO-FETAL TOXICITY

  • Interstitial lung disease (ILD) and pneumonitis, including fatal cases, have been reported with ENHERTU. Monitor for and promptly investigate signs and symptoms including cough, dyspnea, fever, and other new or worsening respiratory symptoms. Permanently discontinue ENHERTU in all patients with Grade 2 or higher ILD/pneumonitis. Advise patients of the risk and to immediately report symptoms.
  • Exposure to ENHERTU during pregnancy can cause embryo-fetal harm. Advise patients of these risks and the need for effective contraception.

 

Contraindications
None.

WARNINGS AND PRECAUTIONS

Interstitial Lung Disease / Pneumonitis
Severe, life-threatening, or fatal interstitial lung disease (ILD), including pneumonitis, can occur in patients treated with ENHERTU. In clinical studies, of the 234 patients with unresectable or metastatic HER2-positive breast cancer treated with ENHERTU, ILD occurred in 9% of patients. Fatal outcomes due to ILD and/or pneumonitis occurred in 2.6% of patients treated with ENHERTU. Median time to first onset was 4.1 months (range: 1.2 to 8.3).

Advise patients to immediately report cough, dyspnea, fever, and/or any new or worsening respiratory symptoms. Monitor patients for signs and symptoms of ILD. Promptly investigate evidence of ILD. Evaluate patients with suspected ILD by radiographic imaging. Consider consultation with a pulmonologist. For asymptomatic ILD/pneumonitis (Grade 1), interrupt ENHERTU until resolved to Grade 0, then if resolved in ≤28 days from date of onset, maintain dose. If resolved in >28 days from date of onset, reduce dose one level. Consider corticosteroid treatment as soon as ILD/pneumonitis is suspected (e.g., ≥0.5 mg/kg prednisolone or equivalent). For symptomatic ILD/pneumonitis (Grade 2 or greater), permanently discontinue ENHERTU. Promptly initiate corticosteroid treatment as soon as ILD/pneumonitis is suspected (e.g., ≥1 mg/kg prednisolone or equivalent). Upon improvement, follow by gradual taper (e.g., 4 weeks).

Neutropenia
Severe neutropenia, including febrile neutropenia, can occur in patients treated with ENHERTU. Of the 234 patients with unresectable or metastatic HER2-positive breast cancer who received ENHERTU, a decrease in neutrophil count was reported in 30% of patients and 16% had Grade 3 or 4 events. Median time to first onset was 1.4 months (range: 0.3 to 18.2). Febrile neutropenia was reported in 1.7% of patients.

Monitor complete blood counts prior to initiation of ENHERTU and prior to each dose, and as clinically indicated. Based on the severity of neutropenia, ENHERTU may require dose interruption or reduction. For Grade 3 neutropenia (Absolute Neutrophil Count [ANC] <1.0 to 0.5 x 109/L) interrupt ENHERTU until resolved to Grade 2 or less, then maintain dose. For Grade 4 neutropenia (ANC <0.5 x 109/L) interrupt ENHERTU until resolved to Grade 2 or less. Reduce dose by one level. For febrile neutropenia (ANC <1.0 x 109/L and temperature >38.3ºC or a sustained temperature of ≥38ºC for more than 1 hour), interrupt ENHERTU until resolved. Reduce dose by one level.

Left Ventricular Dysfunction
Patients treated with ENHERTU may be at increased risk of developing left ventricular dysfunction. Left ventricular ejection fraction (LVEF) decrease has been observed with anti-HER2 therapies, including ENHERTU. In the 234 patients with unresectable or metastatic HER2-positive breast cancer who received ENHERTU, two cases (0.9%) of asymptomatic LVEF decrease were reported. Treatment with ENHERTU has not been studied in patients with a history of clinically significant cardiac disease or LVEF <50% prior to initiation of treatment.

Assess LVEF prior to initiation of ENHERTU and at regular intervals during treatment as clinically indicated. Manage LVEF decrease through treatment interruption. Permanently discontinue ENHERTU if LVEF of <40% or absolute decrease from baseline of >20% is confirmed. When LVEF is >45% and absolute decrease from baseline is 10-20%, continue treatment with ENHERTU. When LVEF is 40-45% and absolute decrease from baseline is <10%, continue treatment with ENHERTU and repeat LVEF assessment within 3 weeks. When LVEF is 40-45% and absolute decrease from baseline is 10-20%, interrupt ENHERTU and repeat LVEF assessment within 3 weeks. If LVEF has not recovered to within 10% from baseline, permanently discontinue ENHERTU. If LVEF recovers to within 10% from baseline, resume treatment with ENHERTU at the same dose. When LVEF is <40% or absolute decrease from baseline is >20%, interrupt ENHERTU and repeat LVEF assessment within 3 weeks. If LVEF of <40% or absolute decrease from baseline of >20% is confirmed, permanently discontinue ENHERTU. Permanently discontinue ENHERTU in patients with symptomatic congestive heart failure.

Embryo-Fetal Toxicity 
ENHERTU can cause fetal harm when administered to a pregnant woman. Advise patients of the potential risks to a fetus. Verify the pregnancy status of females of reproductive potential prior to the initiation of ENHERTU. Advise females of reproductive potential to use effective contraception during treatment and for at least 7 months following the last dose of ENHERTU. Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ENHERTU and for at least 4 months after the last dose of ENHERTU.

Adverse Reactions
The safety of ENHERTU was evaluated in a pooled analysis of 234 patients with unresectable or metastatic HER2-positive breast cancer who received at least one dose of ENHERTU 5.4 mg/kg in DESTINY-Breast01 and Study DS8201-A-J101. ENHERTU was administered by intravenous infusion once every three weeks. The median duration of treatment was 7 months (range: 0.7 to 31).

Serious adverse reactions occurred in 20% of patients receiving ENHERTU. Serious adverse reactions in >1% of patients who received ENHERTU were interstitial lung disease, pneumonia, vomiting, nausea, cellulitis, hypokalemia, and intestinal obstruction. Fatalities due to adverse reactions occurred in 4.3% of patients including interstitial lung disease (2.6%), and the following events occurred in one patient each (0.4%): acute hepatic failure/acute kidney injury, general physical health deterioration, pneumonia, and hemorrhagic shock.

ENHERTU was permanently discontinued in 9% of patients, of which ILD accounted for 6%. Dose interruptions due to adverse reactions occurred in 33% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose interruption were neutropenia, anemia, thrombocytopenia, leukopenia, upper respiratory tract infection, fatigue, nausea, and ILD. Dose reductions occurred in 18% of patients treated with ENHERTU. The most frequent adverse reactions (>2%) associated with dose reduction were fatigue, nausea, and neutropenia.

The most common adverse reactions (frequency ≥20%) were nausea (79%), fatigue (59%), vomiting (47%), alopecia (46%), constipation (35%), decreased appetite (32%), anemia (31%), neutropenia (29%), diarrhea (29%), leukopenia (22%), cough (20%), and thrombocytopenia (20%).

Use in Specific Populations

  • Pregnancy: ENHERTU can cause fetal harm when administered to a pregnant woman. Advise patients of the potential risks to a fetus. There are clinical considerations if ENHERTU is used in pregnant women, or if a patient becomes pregnant within 7 months following the last dose of ENHERTU.
  • Lactation: There are no data regarding the presence of ENHERTU in human milk, the effects on the breastfed child, or the effects on milk production. Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with ENHERTU and for 7 months after the last dose.
  • Females and Males of Reproductive Potential: Pregnancy testing: Verify pregnancy status of females of reproductive potential prior to initiation of ENHERTU. Contraception: Females: ENHERTU can cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential to use effective contraception during treatment with ENHERTU and for at least 7 months following the last dose. Males: Advise male patients with female partners of reproductive potential to use effective contraception during treatment with ENHERTU and for at least 4 months following the last dose. Infertility: ENHERTU may impair male reproductive function and fertility.
  • Pediatric Use: Safety and effectiveness of ENHERTU have not been established in pediatric patients.
  • Geriatric Use: Of the 234 patients with HER2-positive breast cancer treated with ENHERTU 5.4 mg/kg, 26% were ≥65 years and 5% were ≥75 years. No overall differences in efficacy were observed between patients ≥65 years of age compared to younger patients. There was a higher incidence of Grade 3-4 adverse reactions observed in patients aged ≥65 years (53%) as compared to younger patients (42%).
  • Hepatic Impairment: In patients with moderate hepatic impairment, due to potentially increased exposure, closely monitor for increased toxicities related to the topoisomerase inhibitor.
     

To report SUSPECTED ADVERSE REACTIONS, contact Daiichi Sankyo, Inc. at 1-877-437-7763 or FDA at 1-800-FDA-1088 or fda.gov/medwatch. 

Please see accompanying full Prescribing Information, including Boxed WARNING, and Medication Guide.

About Daiichi Sankyo Cancer Enterprise
The mission of Daiichi Sankyo Cancer Enterprise is to leverage our world-class, innovative science and push beyond traditional thinking to create meaningful treatments for patients with cancer. We are dedicated to transforming science into value for patients, and this sense of obligation informs everything we do. Anchored by our DXd antibody drug conjugate (ADC) technology, our powerful research engines include biologics, medicinal chemistry, modality and other research laboratories in Japan, and Plexxikon Inc., our small molecule structure-guided R&D center in Berkeley, CA. For more information, please visit: www.DSCancerEnterprise.com.  


About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders. For more information, please visit: www.daiichisankyo.com.

Media Contacts:

 

Global/US:

Jennifer Brennan

Daiichi Sankyo, Inc.

jbrennan2@dsi.com

+1 908 992 6631 (office)

+1 201 709 9309 (mobile)

 

Japan:

Masashi Kawase

Daiichi Sankyo Co., Ltd.

kawase.masashi.a2@daiichisankyo.co.jp

+81 3 6225 1126 (office)

 

EU:

Lydia Worms

Daiichi Sankyo Europe GmbH

lydia.worms@daiichi-sankyo.eu

+49 (89) 7808751 (office)

+49 176 11780861 (mobile)

Investor Relations Contact:

DaiichiSankyoIR@daiichisankyo.co.jp

 

References

References:

[i] Zhao W. et al. Oncology Reports 40: 759-766, 2018.

[ii] Zaman, S. et al. OncoTargets and Therapy 2019:12 1781–1790.

[iii] Inamura, K. et al. Oncotarget. 2017; 8(17):28725-28735.

[iv] Zeng, P. et al. Nature Scientific Reports 2016;6: e33658.